Canton Strategic Holdings, INC. (CNTN) — SEC Filings

Overview

Canton Strategic Holdings, INC. (CNTN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 31, 2026: Canton Strategic Holdings, Inc. (CNTN) has undergone a significant strategic shift in November 2025, moving from a biotechnology focus to a digital asset treasury strategy centered on Canton Coin (CC) and the Canton Network. The company aims to leverage CC as a utility token for institutional blockc

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Canton Strategic Holdings, INC. is neutral.

Filing Type Overview

Canton Strategic Holdings, INC. (CNTN) has filed 1 D, 2 10-K, 35 8-K, 6 10-Q, 3 DEF 14A, 1 8-K/A, 2 DEFA14A with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• D Filing — D · Apr 15, 2026
• Canton Strategic Pivots to Crypto, Embraces Canton Network for Growth — 10-K · Mar 31, 2026 Risk: high
  Canton Strategic Holdings, Inc. (CNTN) has undergone a significant strategic shift in November 2025, moving from a biotechnology focus to a digital asset treasu
• 8-K Filing — 8-K · Mar 31, 2026
• Tharimmune Inc. Board Shakeup: New Directors, CFO Appointed — 8-K · Dec 12, 2025 Risk: medium
  On December 10, 2025, Tharimmune, Inc. announced the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also elected Ms. Sarah E. Kelly
• Tharimmune Narrows Q3 Loss, Shifts TH104 Focus to Opioid Prophylaxis — 10-Q · Nov 12, 2025 Risk: high
  Tharimmune, Inc. (THAR) reported a net loss of $2.10 million for the three months ended September 30, 2025, a significant improvement from the $3.80 million net
• Tharimmune, Inc. Reports Board and Executive Compensation Changes — 8-K · Nov 10, 2025 Risk: medium
  Tharimmune, Inc. announced on November 7, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the dep
• Tharimmune, Inc. Enters Material Definitive Agreement — 8-K · Nov 7, 2025 Risk: medium
  On November 6, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in
• Tharimmune Announces Board Changes — 8-K · Nov 6, 2025 Risk: medium
  On November 3, 2025, Tharimmune, Inc. announced the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also announced the appointment of
• Tharimmune, Inc. Files 8-K: Regulation FD Disclosure & Other Events — 8-K · Nov 5, 2025 Risk: low
  On November 3, 2025, Tharimmune, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements a
• Tharimmune, Inc. Files 8-K with Material Agreements and Equity Sales — 8-K · Nov 3, 2025 Risk: medium
  On November 3, 2025, Tharimmune, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in unr
• Tharimmune, Inc. Files 8-K with Bylaw Amendments — 8-K · Oct 10, 2025 Risk: low
  On October 10, 2025, Tharimmune, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws and including financial statements and
• Tharimmune, Inc. Files 8-K: Director Changes and Officer Compensation — 8-K · Oct 9, 2025 Risk: medium
  On October 9, 2025, Tharimmune, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Jonathan T. Hunt and
• Tharimmune, Inc. Enters Material Definitive Agreement — 8-K · Oct 6, 2025 Risk: medium
  On October 1, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in
• Tharimmune Seeks Share Increase, Equity Plan Boost, and Future Offering Authority — DEF 14A · Sep 18, 2025 Risk: high
  Tharimmune, Inc. (CNTN) is seeking stockholder approval for three key proposals at its Special Meeting on October 9, 2025. The first proposal, the Authorized Sh
• Tharimmune, Inc. Relocates HQ, Reports Officer/Director Changes — 8-K · Sep 8, 2025 Risk: low
  Tharimmune, Inc. announced on September 2, 2025, a change in its principal executive offices to 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701. This filing
• Tharimmune, Inc. Files 8-K with Financials — 8-K · Sep 5, 2025 Risk: low
  Tharimmune, Inc. filed an 8-K on September 5, 2025, reporting other events and financial statements. The company, formerly known as Hillstream BioPharma Inc. un
• Tharimmune Files 8-K/A Amendment — 8-K/A · Aug 26, 2025 Risk: medium
  Tharimmune, Inc. filed an 8-K/A on August 26, 2025, to amend a previous filing. The amendment pertains to Item 1.01, Entry into a Material Definitive Agreement,
• Tharimmune, Inc. Files 10-Q for Q2 2025 — 10-Q · Aug 14, 2025 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly known as Hillstream BioPharma Inc., is focused on pharmaceutical prep
• Tharimmune Appoints New Chief Medical Officer — 8-K · Aug 7, 2025 Risk: medium
  On August 4, 2025, Tharimmune, Inc. announced the appointment of Dr. Jonathan P. S. Farber as Chief Medical Officer. Dr. Farber brings extensive experience in o
• Tharimmune, Inc. Enters Material Definitive Agreement — 8-K · Jul 31, 2025 Risk: medium
  On July 25, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in De
• Tharimmune, Inc. Enters Material Definitive Agreement — 8-K · Jul 28, 2025 Risk: medium
  On July 23, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company, formerly known
• Tharimmune Announces Board and Executive Changes — 8-K · Jun 24, 2025 Risk: medium
  Tharimmune, Inc. announced on June 22, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depart
• Tharimmune, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jun 20, 2025 Risk: medium
  On June 13, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in De
• Tharimmune Appoints New Directors and Officers, Adjusts Compensation — 8-K · Jun 16, 2025 Risk: medium
  Tharimmune, Inc. announced on June 10, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
• Tharimmune Announces Board Changes and New CFO — 8-K · Jun 11, 2025 Risk: medium
  Tharimmune, Inc. announced on June 11, 2025, the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also elected two new directors, Dr.
• Tharimmune, Inc. Files 8-K on Security Holder Votes — 8-K · Jun 10, 2025 Risk: low
  Tharimmune, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate str
• Tharimmune, Inc. Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Hillstream BioPharma Inc., is in the pharmaceutical prepara
• Tharimmune Board Changes and Officer Compensation — 8-K · May 9, 2025 Risk: low
  Tharimmune, Inc. announced on May 9, 2025, a change in its board of directors. Specifically, Dr. Jonathan M. Roth, a director, has resigned. The company also re
• Tharimmune Files Additional Proxy Materials — DEFA14A · May 2, 2025 Risk: low
  Tharimmune, Inc. filed a Definitive Additional Materials proxy statement on May 2, 2025. The filing relates to the company's proxy materials, indicating it is p
• Tharimmune Inc. Files 2025 Definitive Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Tharimmune, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing details information
• Tharimmune, Inc. Reports Executive and Director Changes — 8-K · Apr 28, 2025 Risk: medium
  On April 28, 2025, Tharimmune, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing indicates the election of new dire
• Tharimmune, Inc. Updates Corporate Address and Contact Info — 8-K · Apr 25, 2025 Risk: low
  On April 24, 2025, Tharimmune, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Route 22 East, Suite
• Tharimmune Appoints New CMO, Board Member — 8-K · Apr 10, 2025 Risk: medium
  On April 9, 2025, Tharimmune, Inc. announced changes to its board of directors, including the appointment of Dr. Jonathan P. S. Farber as Chief Medical Officer
• Tharimmune Faces Delisting Concerns — 8-K · Apr 4, 2025 Risk: high
  Tharimmune, Inc. filed an 8-K on April 1, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as H
• Tharimmune, Inc. Files 2024 Annual Report — 10-K · Mar 26, 2025 Risk: medium
  Tharimmune, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 26, 2025. The company, formerly known as Hillstream BioPharma Inc. until
• Tharimmune, Inc. Files 8-K on Director Changes — 8-K · Feb 27, 2025 Risk: medium
  On February 21, 2025, Tharimmune, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indic
• Tharimmune, Inc. Files 8-K: Material Agreement, Other Events — 8-K · Dec 6, 2024 Risk: medium
  On December 5, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed within the filing. The company also repo
• Tharimmune Board Changes and Officer Compensation — 8-K · Nov 21, 2024 Risk: low
  Tharimmune, Inc. announced on November 20, 2024, a change in its board of directors. Dr. Jonathan M. Roth, who served as a director, has resigned. The company a
• Tharimmune, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 7, 2024 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Hillstream BioPharma Inc., is focused on pharmaceutical
• Tharimmune Files 8-K with Regulatory Updates — 8-K · Sep 30, 2024 Risk: low
  Tharimmune, Inc. filed an 8-K on September 30, 2024, reporting on various events including Regulation FD disclosures, other events, and financial statements. Th
• Tharimmune, Inc. Files 8-K: Material Definitive Agreement — 8-K · Sep 16, 2024 Risk: medium
  On September 11, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements
• Tharimmune, Inc. Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Hillstream BioPharma Inc., is in the pharmaceutical preparat
• Tharimmune, Inc. Files 8-K with Material Agreement — 8-K · Jun 20, 2024 Risk: medium
  On June 18, 2024, Tharimmune, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also r
• Tharimmune to Acquire Bio-Genetics for $1.5M — 8-K · Jun 11, 2024 Risk: medium
  Tharimmune, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests in Bio-Genetics, Inc. f
• Tharimmune, Inc. Files Material Definitive Agreement 8-K — 8-K · Jun 7, 2024 Risk: medium
  On June 7, 2024, Tharimmune, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is in
• Tharimmune Files 8-K: Corporate Updates & Financials — 8-K · May 22, 2024 Risk: low
  Tharimmune, Inc. filed an 8-K on May 22, 2024, reporting amendments to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits.
• Tharimmune, Inc. Files 8-K on Security Holder Votes — 8-K · May 14, 2024 Risk: low
  Tharimmune, Inc. filed an 8-K on May 14, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details ab
• Tharimmune, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Tharimmune, Inc. (CNTN) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Tharimmune, Inc. filed a 10-Q report for the quarterly period ended March 3
• Tharimmune Inc. Files Proxy Statement — DEFA14A · Mar 22, 2024 Risk: low
  Tharimmune, Inc. filed a Definitive Additional Materials proxy statement on March 22, 2024. The filing relates to the company's operations and shareholder matte
• Tharimmune, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Mar 21, 2024 Risk: medium
  Tharimmune, Inc. (CNTN) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Annual meeting scheduled for May 14, 2024. Proposing election of five

Risk Profile

Risk Assessment: Of CNTN's 48 recent filings, 4 were flagged as high-risk, 29 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Canton Strategic Holdings, INC.'s most recent 10-K filing (Mar 31, 2026):

• Revenue: $6.4 million

Key Executives

• Dr. Jonathan T. Hunt
• Ms. Sarah E. Kelly
• Mr. David M. S. Johnson
• Dr. David M. Epstein
• Mr. Robert S. Miller
• Vincent LoPriore
• Sireesh Appajosyula
• David Clarke
• Dr. Jonathan P. S. Farber
• Dr. David J. E. J. Smith
• Mr. David L. M. Smith
• Dr. Jeffrey S. Cherep
• Mr. Michael J. P. Smith
• Dr. Steven M. Altschuler
• Dr. Jonathan M. Roth

Industry Context

Canton Strategic Holdings is operating within the rapidly evolving digital asset and blockchain infrastructure sector, specifically targeting institutional capital markets. The Canton Network's reported processing of over $6 trillion in tokenized real-world assets, including substantial daily U.S. Treasury repo volumes, suggests significant institutional adoption and a potentially large addressable market. However, this space is highly competitive, with numerous blockchain protocols and digital asset solutions vying for market share and developer engagement.

Top Tags

material-agreement (7) · management-change (6) · corporate-governance (6) · board-of-directors (5) · financials (5) · filing (5) · 10-Q (5) · material-definitive-agreement (4) · corporate-action (4) · executive-compensation (3)

Key Numbers

• aggregate market value of non-affiliate voting stock: $6.4 million — as of June 30, 2025, based on $1.94 closing price
• common shares outstanding: 56,656,271 — as of March 26, 2026
• tokenized real-world assets: $6 trillion — processed on Canton Network
• daily U.S. Treasury repo: $350 billion — processed on Canton Network
• date of strategic shift: November 2025 — company pivoted from biotech to digital asset strategy
• next halving of CC issuance: 2029 — expected in the second quarter
• Cash and Cash Equivalents: $7.61M — Increased from $3.56M at Dec 31, 2024, providing liquidity.
• Net Loss (9 months): $6.50M — Reduced from $8.38M in prior year, indicating improved financial performance.
• Net Cash Used in Operating Activities (9 months): $5.69M — Reduced from $7.87M in prior year, showing a decrease in operational cash burn.
• Net Cash Provided by Financing Activities (9 months): $9.74M — Significant capital raised through offerings, crucial for liquidity.
• Research and Development Expenses (Q3): $277,803 — Decreased significantly from $2.28M in Q3 2024, reflecting a shift in R&D strategy.
• Common Shares Outstanding: 35,044,812 — As of November 10, 2025, indicating significant dilution from prior periods.
• General and Administrative Expenses (Q3): $1.82M — Increased from $1.58M in Q3 2024, offsetting some R&D savings.
• Regulatory Pathway: 505(b)(2) — FDA feedback for TH104 PrHPO, potentially accelerating approval.
• SEC File Number: 001-41210 — Identifies the company's filing with the SEC.

Related Companies

THAR

Frequently Asked Questions